Benzimidazolone carboxylic acid derivatives

• US 7,737,163 B2
• Filed: 06/14/2005
• Issued: 06/15/2010
• Est. Priority Date: 06/15/2004
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Ando, Koji, Numata, Toyoharu, Uchida, Chikara, Sone, Hiroki, Iguchi, Satoru, Murata, Yoshinori, Ueki, Tatsuo, Murase, Noriaki
• Primary Examiner(s): Shameem; Golam M
• Application Number:
  US11/153,766
• Publication Number:
  US 20050277672A1
• Time in Patent Office: 1,827 Days
• Field of Search: 546/184, 546/192, 546/196, 546/197, 546/199, 548/300.1, 548/301.7, 548/302.7, 548/304.4, 548/306.1, 514/315, 514/317, 514/320, 514/322, 514/385, 514/386, 514/387
• US Class Current: 514/322
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings

Abstract

This invention relates to compounds of the formula (I):

wherein R¹, R², R³, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT₄ receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer'"'"'s disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Claims

1. The compound:

1-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid, or a pharmaceutically acceptable salt or solvate thereof.

2. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1, with or without at least one pharmaceutically acceptable carrier.

3. A pharmaceutical composition as claimed in claim 2, further comprising at least one pharmacologically active agent in addition to the compound.